NLS Pharmaceutics Director Resigns
Ticker: NCEL · Form: 6-K · Filed: Nov 15, 2024 · CIK: 1783036
| Field | Detail |
|---|---|
| Company | Nls Pharmaceutics LTD. (NCEL) |
| Form Type | 6-K |
| Filed Date | Nov 15, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: director-resignation, governance
Related Tickers: NLS
TL;DR
NLS Pharma director Claudio Bassetti stepping down Nov 30, no drama.
AI Summary
NLS Pharmaceutics Ltd. announced on November 13, 2024, that Claudio Bassetti will resign from its Board of Directors, effective November 30, 2024. This resignation is not due to any disagreements regarding the company's operations, policies, or practices. The filing also mentions amended and restated Articles of Association.
Why It Matters
A director's resignation can signal changes in company strategy or governance, which investors should monitor.
Risk Assessment
Risk Level: low — The resignation is stated to be without material disagreement, indicating it's likely a routine personnel change.
Key Players & Entities
- NLS Pharmaceutics Ltd. (company) — The company filing the report.
- Claudio Bassetti (person) — Director resigning from the Board.
- November 13, 2024 (date) — Date Bassetti notified the company of his resignation.
- November 30, 2024 (date) — Effective date of Bassetti's resignation.
FAQ
Who is resigning from the NLS Pharmaceutics Board of Directors?
Claudio Bassetti is resigning from the Board of Directors.
When is Claudio Bassetti's resignation effective?
The resignation is effective November 30, 2024.
What is the reason for Claudio Bassetti's resignation?
The resignation is not based on any material disagreement with the Company on any matter relating to its operations, policies or practice.
What other significant update is mentioned in the filing?
The filing also mentions amended and restated Articles of Association.
What is the Commission file number for NLS Pharmaceutics Ltd.?
The Commission file number is 001-39957.
Filing Stats: 536 words · 2 min read · ~2 pages · Grade level 11.3 · Accepted 2024-11-15 17:00:04
Filing Documents
- ea0221081-6k_nlspharma.htm (6-K) — 20KB
- ea022108101ex99-1_nlspharma.htm (EX-99.1) — 470KB
- 0001213900-24-099171.txt ( ) — 491KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. NLS Pharmaceutics Ltd. Date: November 15, 2024 By: /s/ Alexander Zwyer Name: Alexander Zwyer Title: Chief Executive Officer 2